460 Studies Now Enrolling
AN OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB INPATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO HAVE HAD A SUBOPTIMALRESPONSE TO AN ADEQUATE COURSE OF DISEASE-MODIFYING TREATMENT
A study for patients with Multiple Sclerosis (MS) using study drug ocrelizumab for disease-modifying treatment
| Sponsor: | Genentech, Inc. |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ8211 |
| U.S. Govt. ID: | NCT02637856 |
| Contact: | Claire Riley: 212-305-6876 / csr53@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to see if ocrelizumab (study drug) will stabilize, or potentiallyimprove the signs and symptoms of your MS. Ocrelizumab is a type of drug called amonoclonal antibody. Monoclonal antibodies act like your bodys immune system andattach to certain cells in order to attack germs and other illnesses in your body.Ocrelizumab attaches to certain types of cells (B cells) that are thought to play a role in
This study is closed
